Patient-Reported Symptom Burden and Daily Impairment in cGVHD
According to a study in Cancer Medicine, there is a lack of patient-reported evidence on the symptom burden and impact on daily activities of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT). Researchers conducted a survey and reported that respondents identified high cGVHD symptom burden and felt their symptoms significantly interfered with physical functioning and activities of daily living (ADL). ...
Advertisement

Latest News

Advertisement
Advertisement
Our Contributors

Expert Interviews

Conference Highlights

Cecilia BrownConferences | October 5, 2022
The GVHD rate was around 5% in patients receiving Orca-T, a high-precision, regulatory T-cell-engineered donor product.
Read More
Cecilia BrownConferences | October 5, 2022
GVHD occurred more with a fludarabine-based flipped conditioning regimen than with a cyclophosphamide-based flipped regimen.
Cecilia BrownConferences | October 5, 2022
The presence and number of clonal plasma cells in an autograft are predictive of posttransplant outcomes in multiple myeloma.
Cecilia BrownConferences | October 5, 2022
Noncryopreserved and cryopreserved peripheral blood stem cells (PBSC) lead to similar patient outcomes after transplant.
Cecilia BrownConferences | October 5, 2022
Most patients did not have extensive chronic GVHD after a mismatched transplant with this pretransplant conditioning regimen.
Cecilia BrownConferences | October 5, 2022
Patients transplanted with omidubicel had better quality of life than patients transplanted with umbilical cord blood.